Murray T Jock
Dalhousie School of Medicine, Halifax, Canada.
J Neurol Sci. 2009 Feb 1;277 Suppl 1:S3-8. doi: 10.1016/S0022-510X(09)70003-6.
For centuries, it was recognised that there was a condition characterised by episodic and progressive neurological deterioration, classified as 'paraplegia'. Some early cases of 'paraplegia' have been described in sufficient detail to recognise a condition resembling what we now call multiple sclerosis and these cast an interesting light on the approach to therapy before the disease had a name. Multiple sclerosis was differentiated and 'framed' as a separate identifiable entity by von Frerichs, Vulpian, Charcot and others in the mid-nineteenth century. Once framed by its pathology, clinical picture, course and prognosis, cases were diagnosed by others around the world. As knowledge of the disease increased, theories of cause and approaches to treatment increased so that a review in 1935 covered 158 treatments used in MS. There were subsequent waves of therapies including anticoagulants, antibiotics, histamine desensitisation, various diets, vaccines and anti-cancer agents, as well as numerous claims of 'cures'. After the 1960s the methodology for carrying out randomised clinical trials became better defined, aided by improved disease classification and disability scales. As data accumulated, theories were tested to account for observations of genetic influences, environmental factors, geographical variations, infections and immunological changes. The development of multiple sclerosis societies advanced research and public education and changed attitudes towards the disease. At the same time, attitudes of physicians towards management of people with multiple sclerosis changed. In the last fifty years, the major advances have been in basic research to elucidate the mechanisms and processes underlying the disease, the development of imaging techniques (MRI) and the development of immunomodulatory drugs which, for the first time, are altering the outcome of the disease. We have now entered the therapeutic era of multiple sclerosis, with continual major advances bringing hope and benefit to people with multiple sclerosis.
几个世纪以来,人们认识到有一种疾病,其特征是发作性和进行性神经功能恶化,被归类为“截瘫”。一些早期的“截瘫”病例有足够详细的描述,足以识别出一种类似于我们现在所说的多发性硬化症的疾病,这些病例为该疾病尚无名称时的治疗方法提供了有趣的线索。19世纪中叶,冯·弗雷里希斯、维尔皮安、夏科等人将多发性硬化症区分并“界定”为一个独立的可识别实体。一旦根据其病理、临床表现、病程和预后进行了界定,世界各地的其他人就可以对病例进行诊断。随着对该疾病认识的增加,病因理论和治疗方法也不断增加,以至于1935年的一篇综述涵盖了用于多发性硬化症的158种治疗方法。随后出现了一波又一波的治疗方法,包括抗凝剂、抗生素、组胺脱敏、各种饮食、疫苗和抗癌药物,以及众多“治愈”的说法。20世纪60年代以后,随着疾病分类和残疾量表的改进,进行随机临床试验的方法得到了更好的界定。随着数据的积累,各种理论经过了检验,以解释对遗传影响、环境因素、地理差异、感染和免疫变化的观察结果。多发性硬化症协会的发展推动了研究和公众教育,并改变了人们对该疾病的态度。与此同时,医生对多发性硬化症患者管理的态度也发生了变化。在过去的五十年里,主要进展在于基础研究,以阐明该疾病的潜在机制和过程、成像技术(MRI)的发展以及免疫调节药物的开发,这些药物首次改变了该疾病的结局。我们现在已经进入了多发性硬化症的治疗时代,持续的重大进展给多发性硬化症患者带来了希望和益处。